Rampur Distillery Lights Up Diwali in Times Square New York City
1.11.2024 12:30:00 EET | Business Wire | Press release
Rampur Distillery celebrates Diwali 2024 with a striking display at Times Square, New York City.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030298390/en/
This #Diwali, we lit up Times Square with Rampur Indian Single Malt Asava - Best World Whisky! (Photo: Business Wire)
"Happy Diwali from all of us at Rampur Distillery! This festival symbolizes light, unity, and new beginnings. As we celebrate, we're proud to showcase our award-winning Rampur Indian Single Malt Whisky and introduce our Jugalbandi collection series, featuring Jugalbandi #5 and #6 expressions, set to launch in the United States in 2025. Times Square reflects our rich heritage and commitment to expanding our global presence. Together, let’s embrace the spirit of Diwali and look forward to a prosperous year ahead!" - Mr. Sanjeev Banga, President of International Business at Radico Khaitan.
In 2016, Rampur Distillery made a significant entry into the global whisky market with the launch of its flagship Rampur Select Indian Single Malt Whisky, quickly garnering attention for its rich flavor profile and exceptional craftsmanship.
As Diwali 2024 approaches, the distillery proudly celebrates its award-winning Rampur Asava, honored as the Best World Whisky 2023 by the John Barleycorn Awards. This accolade is a testament to Rampur's commitment to innovation and excellence in whisky-making.
Rampur Distillery has also expanded its luxury portfolio, offering a range of premium expressions crafted with meticulous attention to detail. Each expression showcases unique flavor profiles that reflect the artistry of Indian whisky-making. With the latest addition, Rampur Barrel Blush, the distillery continues to blend traditional techniques with modern influences, appealing to whisky enthusiasts and connoisseurs worldwide.
Mr. Kunal Madan, Vice President of International Business at Radico Khaitan, shares, “Happy Diwali! We are thrilled to celebrate this festive season with everyone. Alongside our award-winning products, we’re excited to share the news that we have recently launched Rampur Barrel Blush, our new expression that embodies the spirit of Diwali through its celebration of new beginnings and rich heritage. Just as Diwali signifies renewal and joy, this whisky invites you to share special moments with loved ones. Its intricate flavors complement the warmth of the season, making it a lovely choice to toast to prosperity and cherished memories. Cheers to family, festivities, and the joy of togetherness!”
Rampur Whisky offerings include:
- Rampur Select
- Rampur Double Cask
- Rampur Asava
- Rampur Barrel Blush
- Rampur Jugalbandi Series
- Sangam World Malt
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030298390/en/
Contacts
exports@radico.co.in
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 10:00:00 EET | Press release
Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom